Literature DB >> 15233969

A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets.

Shiro Tochizawa1, Seiji Akamatsu, Yoshihiro Sugiyama, Masahiro Muraguchi, Yasukazu Ohmoto, Yukihisa Ono, Hiroshi Ishikawa, Akira Tanigami, Takumi Sumida, Toyoki Mori.   

Abstract

INTRODUCTION: It is expected that expression levels in the peripheral blood mononuclear cells (PBMC) of IFNAR2, a subunit of the interferon (IFN) receptor, may be a marker for predicting IFN response. In the present study, we have established a rapid and convenient method for assaying IFNAR2, using flow cytometry.
METHODS: Fifty microliters of whole blood from healthy volunteers was treated with an anti-IFNAR2 antibody and stained with a Fluorescein isothiocyanate (FITC)-conjugated secondary antibody. In addition, the cells were stained with subset-specific antibodies conjugated with phycoerythrin (PE) and PE covalently linked to cyanin 5 at the same time. The mean FITC-fluorescence intensities were analyzed separately by gating on subset-specific regions.
RESULTS: IFNAR2 was detected in most lymphocytes, monocytes, and granulocytes, although IFNAR2 expression was higher in the monocytes and granulocytes than in the lymphocytes. The intra- and interdaily variations of IFNAR2 in lymphocytes, monocytes, and granulocytes were small. Among the lymphocyte subsets, IFNAR2 showed high expression in natural killer (NK) cells and low expression in T lymphocytes. The effect of IFN-alpha on IFNAR2 expression was examined in vitro. A down-regulation of IFNAR2 was observed by IFN-alpha above 100 IU/ml. DISCUSSION: This assay may be useful for examining IFNAR2 in various leukocyte subsets, separately, as well as providing a rapid and easy method for monitoring expression of type I IFN receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233969     DOI: 10.1016/j.vascn.2004.02.003

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  5 in total

1.  Alteration of interferon-α/β receptors in chronic hepatitis B patients.

Authors:  Fanli Meng; Jiefei Wang; Jian Ge; Xiaopeng Fan; Bing Wang; Liyan Han; Tatiana Kisseleva; YongHan Paik; David A Brenner; Kai Wang
Journal:  J Clin Immunol       Date:  2011-03-29       Impact factor: 8.317

2.  Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.

Authors:  Romy Strauß; Thomas Rose; Shaun M Flint; Jens Klotsche; Thomas Häupl; Markus Peck-Radosavljevic; Taketoshi Yoshida; Chieko Kyogoku; Alexandra Flechsig; Amy M Becker; Kathryn H Dao; Andreas Radbruch; Gerd-Rüdiger Burmester; Paul A Lyons; Laurie S Davis; Falk Hiepe; Andreas Grützkau; Robert Biesen
Journal:  J Mol Med (Berl)       Date:  2017-03-29       Impact factor: 4.599

3.  Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients.

Authors:  Diana L Simons; Gerald Lee; John M Kirkwood; Peter P Lee
Journal:  J Transl Med       Date:  2011-05-05       Impact factor: 5.531

4.  HIV infection does not alter interferon α/β receptor 2 expression on mucosal immune cells.

Authors:  Julia Ickler; Sandra Francois; Marek Widera; Mario L Santiago; Ulf Dittmer; Kathrin Sutter
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

5.  Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis.

Authors:  Takao Kamai; Yoshiaki Yanai; Kyoko Arai; Hideyuki Abe; Tomonori Yamanishi; Masashi Kurimoto; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2007-08-15       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.